MAPT and Alzheimer disease: They also play important roles in the development of new drug therapies.[25] The existing biomarkers used for diagnosing AD include; 42 amino acid forms of amyloid β in the CSF; Total and phosphorylated tau proteins in CSF.[26] Aβ combined with p tau and t tau in the CSF has been established as an acceptable biomarker for the diagnosis of AD.